Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Mirum Pharmaceuticals Inc. (MIRM)

NASDAQ: MIRM · Pharmaceutical Preparations · Foster City, CA

Our rating: Positive

Positive reaffirmed at $96.97, moderate conviction, November 4, 2026.

Breaks if: Revenue growth for the next full fiscal year prints below 25% year-on-year, or free cash flow turns negative for two consecutive reported quarters — either condition signals that the commercial momentum underwriting this multiple has broken down and the Positive call does not hold.

Key figures

Market value$6.3B
Revenue, last 12 months$671M
Net income, last 12 months−$904M
Free cash flow, last 12 months−$274M
Price to earningsn/a
Free cash flow yield−4.4%
Dividend yield0.0%
Operating margin−133.6%
Return on equity−760.0%
Beta to the S&P 5000.84
Volatility, annualized48.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$186M39.6%$-0.87−$6M
June 30, 2026$176M37.9%$-1.06−$44M
March 31, 2026$160M43.3%$-13.43−$229M
December 31, 2025$149M49.8%$-0.12$5M
September 30, 2025$133M47.2%$0.05$39M
June 30, 2025$128M64.1%$-0.12$12M
March 31, 2025$112M61.2%$-0.30−$2M
December 31, 2024$99M42.9%$-0.49−$5M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 25 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.